MariMed Inc (MRMD) Stock Analysis

Verdict: AVOID

A distressed valuation play trapped by a $100M debt load and stagnant growth—survival depends on federal rescheduling or a capital infusion.

Investment score: 38/100

Analysis as of 2026-06-22

Is MariMed Inc stock worth reviewing? The TradeMates thesis

MariMed is priced for failure, and while the $0.07 entry is near historical lows, the deteriorating balance sheet and lack of a near-term catalyst make this a high-risk gamble.

7-factor investment score

Valuation: 65/100 (weight 20%)
Financial Health: 25/100 (weight 15%)
Technical Momentum: 15/100 (weight 15%)
Earnings Quality: 55/100 (weight 15%)
Insider Sentiment: 40/100 (weight 10%)
Analyst Consensus: 30/100 (weight 10%)
Risk-Adjusted Return: 35/100 (weight 15%)

MariMed Inc opportunities and risks

What speaks for MRMD

Extreme Valuation Gap vs. DCF

What speaks against MRMD

Solvency and Debt Service Risk

Peers and competitors

DARE
QCLS
IGC
PVCT
AYTU

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
MRMD	n/a	0.2x	10.8x	36.0%	-7.8%	22.1%
DARE	n/a	17.5x	n/a	5.6%	-1038.8%	-50.1%
QCLS	n/a	0.0x	n/a	0.0%	0.0%	-134.2%
IGC	n/a	23.0x	n/a	29.7%	-552.1%	-23.0%
PVCT	n/a	475.3x	n/a	96.8%	-9775.3%	-9.5%
AYTU	n/a	0.3x	n/a	62.5%	-60.2%	9.1%
Peer median	n/a	17.5x	n/a	29.7%	-552.1%	-23.0%

Frequently asked questions about MariMed Inc (MRMD)

Is MRMD stock a good investment?

The TradeMates model rates MariMed Inc as AVOID with an investment score of 38/100. MariMed is priced for failure, and while the $0.07 entry is near historical lows, the deteriorating balance sheet and lack of a near-term catalyst make this a high-risk gamble. This is algorithmic model output, not personal investment advice.

Is MRMD stock a buy?

The TradeMates model verdict for MRMD is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.